General Information of Drug (ID: DMJ7WRI)

Drug Name
GCC-1290K Drug Info
Synonyms
GC-1290K; GC-2101; GCC-1290A; GCC-1290K (salt formulation, oral), Green Cross; Dopamine modulators (Parkinson's disease, oral), Kangwon University/Green Cross; (+)-3-hydroxymorphinan; 3-HM; 3-HM prodrugs (Parkinson's disease), Green Cross; 3-hydroxymorphinan prodrugs (Parkinson's disease), Green Cross
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 1 [1]
Cross-matching ID
PubChem CID
46213529
TTD Drug ID
DMJ7WRI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolperisone DMA2GHJ Muscle spasm MB47.3 Approved [2]
Eperisone DM1SMAI Muscle spasm MB47.3 Phase 3 [3]
Drug(s) Targeting Protein kinase C (PRKC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Synthetic hypericin DMXU4ON Virus infection 1A24-1D9Z Phase 3 [4]
APH-0812 DM756GE Human immunodeficiency virus-1 infection 1C62 Phase 2 [5]
CYCLOPLATAM DMXR8WN Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
AEB07 DMJVN89 Transplant rejection NE84 Phase 2 [7]
HO/03/03 DMA6HQJ Diabetic foot ulcer BD54 Phase 2 [8]
Bryostatin-1 DM1JOXY Alzheimer disease 8A20 Phase 2 [9]
LXS196 DM65MEL Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
SAFINGOL DMBGUDR Psoriasis vulgaris EA90 Phase 1 [11]
AEB701 DM8I4G0 Melanoma 2C30 Phase 1 [12]
Tecadenoson DM9T6MS Atrial fibrillation BC81.3 Discontinued in Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein kinase C (PRKC) TTYVX59 NOUNIPROTAC Modulator [1]
Voltage-gated calcium channel (Cav) TTCRJKY NOUNIPROTAC Modulator [1]

References

1 Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
2 Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
3 Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305.
4 Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
5 Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
6 Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
7 What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
8 WO patent application no. 2014,0853,81, Pharmaceutical combinations.
9 Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol. 2023 Jun 7;14:1187411.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71.
12 Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
13 Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63.